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Purpose: Outcomes in patients with Fabry disease receiving
migalastat during the phase 3 FACETS trial (NCT00925301) were
evaluated by phenotype.
Methods: Data were evaluated in two subgroups of patients with
migalastat-amenable GLA variants: “classic phenotype” (n= 14;
males with residual peripheral blood mononuclear cell α-
galactosidase A <3% normal and multiorgan system involvement)
and “other patients” (n= 36; males not meeting classic phenotype
criteria and all females). Endpoints included estimated glomerular
filtration rate (eGFR), left ventricular mass index (LVMi),
Gastrointestinal Symptoms Rating Scale diarrhea subscale
(GSRS-D), renal peritubular capillary (PTC) globotriaosylceramide
(GL-3) inclusions, and plasma globotriaosylsphingosine (lyso-Gb3).
Results: Baseline measures in the classic phenotype patients
suggested a more severe phenotype. At month 24, mean (SD)
annualized change in eGFRCKD-EPI with migalastat was −0.3 (3.76)
mL/min/1.73 m2 in the classic phenotype subgroup; changes in
LVMi, GSRS-D, and lyso-Gb3 were −16.7 (18.64) g/m
2, −0.9
(1.66), and −36.8 (35.78) nmol/L, respectively. At month 6, mean
PTC GL-3 inclusions decreased with migalastat (−0.8) and
increased with placebo (0.3); switching from placebo to migalastat,
PTC inclusions decreased by −0.7. Numerically smaller changes in
these endpoints were observed in the other patients.
Conclusion: Migalastat provided clinical benefit to patients with
Fabry disease and amenable variants, regardless of disease severity.
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INTRODUCTION
Fabry disease (OMIM 301500) is a devastating, rare, and
progressive X-linked lysosomal disorder caused by pathogenic
variants in the GLA gene, resulting in functional deficiency of
α-galactosidase A (α-Gal A).1,2 This causes accumulation of
globotriaosylceramide (GL-3 or Gb3) within lysosomes in
various tissues, producing a wide variety of clinical symptoms
and manifestations, including peripheral neuropathy, cardio-
vascular disease, stroke, end-stage renal disease, gastrointestinal
disorders, and premature death.1,2 Although some GLA variants
do not appear to cause disease,1 more than 1000 disease-causing
variants have been reported, of which ~60% are missense.3,4 In
males, disease severity is generally inversely related to residual
α-Gal A activity with variants resulting in near or complete loss
of function associated with the “classic” early-onset form of the
disease.1 Females generally have later symptom onset than
males, but can develop the classic phenotype due to skewed X
chromosome inactivation pattern.5,6
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Enzyme replacement therapy (ERT) has been the current
standard treatment for Fabry disease. ERT has been shown
to reduce disease substrate (i.e., GL-3 and plasma globotriaosyl-
sphingosine [lyso-Gb3]) and symptoms.
1,2,7–9 However,
response to treatment is dependent on several factors including
disease severity, and the amount of organ damage present at
treatment initiation.10–13 Furthermore, lifelong, biweekly intra-
venous ERT infusions are a burden, which can result in delayed
treatment initiation and reduced compliance. Infusion reactions
to ERT have been reported,10 and development of anti-drug
antibodies can reduce the efficacy of ERT, as demonstrated in a
5-year retrospective analysis in which 40% of males had serum-
mediated antibody inhibition of agalsidase activity.14
Migalastat, a first-in-class, orally administered small mole-
cule, is a pharmacological chaperone that binds to and
stabilizes amenable mutant forms of α-Gal A, facilitating
lysosomal trafficking and increasing lysosomal enzyme
activity.4,15–19 Amenable mutant forms of α-Gal A are
identified using the migalastat amenability assay, which
measures migalastat-induced changes in human embryonic
kidney (HEK) cells that are transfected with DNA plasmids
containing GLA variants.4 Established criteria for amenability
are an increase in α-Gal A activity ≥1.2-fold above baseline
and an absolute increase of ≥3% of wild-type (WT) α-Gal A
after incubation with 10 µM migalastat.4
In patients with amenable variants, migalastat is a treatment
option. In the phase 3, placebo-controlled FACETS study
(ClinicalTrials.gov; NCT00925301) in patients with Fabry
disease and amenable variants who were either ERT-naive or
had not received ERT within the past 6 months, migalastat led
to reduced substrates in kidney and plasma, stabilized renal
function, reduced cardiac mass, and improved gastrointestinal
symptoms.20 In the phase 3, active-controlled ATTRACT
study (ClinicalTrials.gov; NCT01218659) in ERT-experienced
patients, migalastat was associated with a reduction in cardiac
mass, had similar effects on renal function compared with
ERT, and was generally well-tolerated.19 These results led to
the approval of migalastat in the European Union, Switzer-
land, Australia, Republic of Korea, Israel, and Japan for the
treatment of Fabry disease in patients over 16 years of age,
with amenable GLA variants and GFR ≥30 mL/min/1.73 m2
(refs.15,21). In addition, migalastat is approved in Canada and
the United States for the long-term treatment of Fabry disease
in adults (≥18 years old) with amenable GLA variants.22,23
The objective of the present analyses was to assess
the clinical benefit of migalastat in the subset of male patients
with the classic phenotype in the FACETS trial (i.e.,
multiorgan system involvement and residual peripheral blood
mononuclear cell [PBMC] α-Gal A activity <3% of normal).20
Results in male patients not meeting classic phenotype criteria
and all female patients were also assessed.
MATERIALS AND METHODS
In vitro assays
Methodology for the Good Laboratory Practice (GLP)-
validated in vitro assay in HEK-293 cells has been published.4
In brief, plasmids containing WT or mutated α-Gal A
complementary DNA (cDNA) were used to transfect
HEK-293 cells; transfected cells were then incubated in the
presence or absence of 10 µmol/L migalastat for 5 days, after
which cell lysates were assayed for α-Gal A activity. Variants
meeting the prespecified criteria for amenability in the assay
were categorized as amenable.4
FACETS phase 3 study design
The multicenter, phase 3, randomized, placebo-controlled,
double-blind FACETS trial to evaluate the efficacy and safety
of migalastat in patients with Fabry disease and amenable
variants has been described in detail.20 Briefly, stage 1 of
the study consisted of a 6-month, double-blind treatment
period in which patients were randomly assigned to receive
migalastat 150 mg or placebo every other day. After stage 1,
patients could receive open-label migalastat 150 mg every
other day for an additional 6 months, and another 12 months
during an open-label extension.
The study was approved by the institutional review board or
ethics committee at each participating center and was
conducted in accordance with the International Conference
on Harmonization and Good Clinical Practice guidelines and
the principles of the Declaration of Helsinki; all patients
provided written informed consent.
Clinical analyses
Two subgroups of patients with amenable variants enrolled in
the FACETS study were identified for evaluation: “classic
phenotype” and “other patients.” The classic phenotype
subgroup included male patients with the classic phenotype
of Fabry disease and migalastat-amenable variants; these
patients had residual PBMC α-Gal A activity <3% normal and
multiorgan system involvement, defined as two or more of the
following organ system involvements: renal, cardiac, central
nervous system, neuropathic pain, and gastrointestinal
symptoms.20 The other patients subgroup included male
patients with migalastat-amenable variants who did not meet
the criteria defined above and all females.17,20
Changes in measurements of disease severity from baseline
are reported. Detailed methodology has been published.20
Annualized rates of change from baseline to month 24 in
estimated glomerular filtration rate using the Chronic Kidney
Disease Epidemiology Collaboration equation (eGFRCKD-EPI)
and GFR measured using iohexol clearance (mGFRiohexol)
were calculated based on the slope of the linear regression
between the observed values and the assessment times. Mean
change from baseline to month 24 in left ventricular mass
index (LVMi) was calculated based on 2D or M-mode
echocardiograms assessed by a single, blinded reader at a
central laboratory. Changes from baseline in number of GL-3
inclusions per renal peritubular capillary (PTC) were based on
kidney biopsies performed at baseline, month 6, and month
12, which were assessed per BLISS methodology performed by
3 independent, blinded pathologists.20,24 The same three
pathologists qualitatively assessed GL-3 changes in podocytes,
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endothelial cells, and mesangial cells. Change from baseline to
month 24 in plasma lyso-Gb3 levels was based on measure-
ments of retained iohexol plasma samples from each time
point. Twenty-four-hour urine protein levels were measured
by a central laboratory. PBMC α-Gal A activity was measured
with a fluorescence assay of PBMC lysates and normalized to
total protein.4
The Gastrointestinal Symptoms Rating Scale was used to
assess change from baseline to month 24 in diarrhea
symptoms (GSRS-D). A response in the GSRS-D was defined
as a reduction ≥0.33. The minimal clinically important
difference (MCID) of 0.33 was based on estimates from the
literature on several non-Fabry gastrointestinal disorders in
which diarrhea is prominent.25,26 Distribution-based esti-
mates of MCID in Fabry disease were based on the change
from baseline in the placebo arm of the FACETS study,
generating an MCID of 0.35 based on half the standard
deviation,20 supporting an MCID for GSRS-D of 0.33 in Fabry
patients.
For all outcomes except PTC GL-3 inclusions, data are
pooled for patients within the designated subgroups (classic
phenotype and other patients) regardless of treatment
allocation for the first 6 months (migalastat or placebo).
Change from baseline to month 24 data are the change from
baseline to month 24 for patients randomized to migalastat
in stage 1 of the study and the change from month 6 (start of
migalastat) to month 24 in patients randomized to placebo in
stage 1.
All data were derived from post hoc analyses and formal
statistical testing was not performed. Data were analyzed
descriptively using mean, standard deviation (SD) or standard
error (SE), and 95% confidence intervals (CIs).
RESULTS
In vitro activity
For the GLA variants found in male patients enrolled in this
study who met the criteria for the classic phenotype, the mean
absolute increase in α-Gal A activity with 10 µM migalastat
in vitro was 24.8% of WT activity; mean activity increased by
8.2-fold above baseline (Table 1). For all other variants, mean
absolute increase in α-Gal A activity in vitro was 24.5% of




The classic phenotype subgroup includes 14 males with the
classic phenotype (16–62 years old). The other patients
subgroup includes 36 patients (4 males with nonclassic
phenotype [33–58 years old], 32 females [27–68 years old]).
Disease severity of patients in the classic phenotype subgroup
was evident from baseline measurements of variables and
medical history, indicating multisystem involvement (Table 2
and Fig. 1a–e). Mean (SD) baseline eGFRCKD-EPI values were
87.8 (33.6) and 95.3 (19.6) mL/min/1.73 m2, and mean (SD)
baseline mGFRiohexol values were 78.6 (22.9) and 88.2 (22.0)
mL/min/1.73 m2 in the classic phenotype and other patients
subgroup, respectively.
GLA variants in male patients with the classic phenotype
were p.Ile253Thr (n= 2), p.Pro259Arg (n= 2), p.Gly183Asp,
p.Leu243Phe, p.Cys174Arg, p.Asp55Val/Gln57Leu, p.Gly144-
Val, p.Arg301Gln, p.Gly373Ser, p.Asp322Glu, p.Gly325Arg,
and p.Tyr216Cys (n= 1 each).
Six (43%) male patients with the classic phenotype were
taking angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers, or renin inhibitors at baseline; the dosages
of these medications had been stable for ≥4 weeks before the
screening visit and did not change during the study.
Renal function
The mean (SD) annualized rate of change in eGFRCKD-EPI from
baseline to month 24 was−0.3 (3.76) mL/min/1.73m2 (95% CI:
−2.80, 2.25; n= 11) in the classic phenotype subgroup and
−0.3 (4.47) mL/min/1.73m2 (95% CI: −2.0, 1.4; n= 30) in
other patients (Fig. 1a; individual values for male patients with
the classic phenotype in Table S1). Median annualized rates of
change in the classic phenotype and other patients subgroups
were 0.25 mL/min/1.73 m2 (min, max: −8.6, 4.3) and 0.33
mL/min/1.73 m2 (min, max: −13.8, 7.4), respectively. Mean
(SD) annualized rate of change in mGFRiohexol was −3.0
(6.04) mL/min/1.73 m2 (95% CI: −7.65, 1.64; n= 9) in the
classic phenotype subgroup and −1.0 (8.66) mL/min/1.73 m2
(95% CI: −4.39, 2.33; n= 28) in other patients. One male
patient with the classic phenotype had a reduction of −16
mL/min/1.73 m2 from month 6 to month 24. Median (range)
change in mGFRiohexol from baseline to month 24 was −1.03
mL/min/1.73 m2 (min, max: −16.2, 3.0) in the classic
phenotype subgroup and −0.34 mL/min/1.73 m2 (min, max:
−20.4, 15.8) in the other patients subgroup.
Twenty-four-hour urine protein levels showed small increases
from baseline to month 24 in both subgroups. Baseline mean
(SD) 24-hour urinary protein excretion values were 767.7
(710.7) (95% CI: 357.4, 1178.0; n= 14) and 360.6 (508.7) (95%
CI: 183.1, 538.1; n= 34) mg/24 hours in the classic phenotype
and other patients subgroups, respectively. Mean (SD) changes
from baseline to month 24 in 24-hour urine protein were 271.3
(419.6) (95% CI: −79.5, 622.0; n= 8) and 168.0 (494.4) (95%
CI: −20.0, 356.1; n= 29) mg/24 hours in the classic phenotype
and other patients subgroups, respectively.
Results were similar to those reported for the overall
amenable FACETS population, in which migalastat stabilized
eGFR in patients with amenable GLA variants, with mean
(SE) annualized changes from baseline to month 24 in
eGFRCKD-EPI and mGFRiohexol of −0.3 (0.66) and −1.5 (1.33)
mL/min/1.73 m2, respectively.20
Cardiac geometry
Migalastat led to reductions in LVMi in both subgroups. Of
note, mean (SD) baseline LVMi values were 114.3 (27.3) g/m2
in male patients with the classic phenotype (n= 14) and 88.2
(32.3) g/m2 in other patients (n= 30). Seven (50%) males
with the classic phenotype and 4 (11%) in the other patients
GERMAIN et al ARTICLE
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subgroup had left ventricular hypertrophy (LVH; >115 g/m2
for males; >95 g/m2 for females) at baseline. Mean (SD)
change from baseline to month 24 in LVMi was −16.7 (18.64)
g/m2 (95% CI: −31.1, −2.4; n= 9) in males with the classic
phenotype and −3.2 (18.66) g/m2 (95% CI: −12.5, 6.1; n=
18) in other patients (Fig. 1b; individual values for male
patients with the classic phenotype in Table S1).
By contrast, LVMi change in the overall migalastat-treated
amenable population in FACETS was −7.7 g/m2 (95% CI:
−15.4, −0.01; n= 27) after 18–24 months of treatment with
migalastat, with larger decreases in the subgroup of patients
with LVH (−18.6 g/m2 [95% CI: −38.2, 1.0]; –11.5%; n= 8)
(ref. 20).
Gastrointestinal signs and symptoms
Mean (SD) GSRS-D scores at baseline were 2.4 (1.69; n= 14)
in the classic phenotype subgroup and 2.1 (1.49; n= 36) in
the other patients subgroup. Eight (57%) male patients with
the classic phenotype had diarrhea symptoms at baseline
(GSRS-D score ≥1). In the classic phenotype subgroup,
6 months of treatment (stage 1) with migalastat improved
(reduced) scores in GSRS-D (mean [SD] change from baseline
−0.3 [0.77]; 95% CI: –1.0, 0.4; n= 7), whereas patients treated
with placebo had a small increase (0.2 [0.46]; 95% CI: –0.2,
0.7; n= 7).
Male patients with the classic phenotype benefited from
continuing treatment with migalastat or by switching from
placebo to migalastat. By 24 months, the mean (SD) change
from baseline in diarrhea symptoms was −0.9 (1.66; n= 10)
(Fig. 1c; individual values in Table S1). Seven of the 8 (88%)
males with the classic phenotype that had diarrhea symptoms
at baseline achieved an MCID reduction of 0.33 in GSRS-D.
The corresponding change in other patients was −0.5 (1.01; n
= 31) at month 24.
These results are similar to those of the overall amenable
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Fig. 1 Measurements of disease severity and treatment effect in the classic phenotype and other patient subgroups. (a) Mean annualized rate of
change in estimated glomerular filtration rate (eGFR) and measured glomerular filtration rate (mGFR) from baseline to month 24. (b) Mean change in LVMi
from baseline to month 24. (c) Mean change in GSRS-D from baseline to month 24. (d) Mean change from baseline to month 12 in average number of GL-3
inclusions per peritubular capillary. Within each subgroup, patients are grouped according to treatment allocation (migalastat to migalastat or placebo to
migalastat). (e) Mean change from baseline to month 24 in plasma lyso-Gb3.
aGroup is comprised of patients who switched from placebo to migalastat at
month 6. bData are mean (SD) number of GL-3 inclusions per peritubular capillary at month 6 (i.e., after 6 months of placebo treatment). The upper cutoff
value for normal plasma lyso-Gb3 level is 2.4 nmol/L.38 eGFRCKD-EPI estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology
Collaboration equation, GL-3 globotriaosylceramide, GSRS-D Gastrointestinal Symptoms Rating Scale diarrhea subscale, LVMi left ventricular mass index,
lyso-Gb3 plasma globotriaosylsphingosine, mGFRiohexol glomerular filtration rate measured using iohexol clearance.
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variants treated with migalastat had mean changes in GSRS-D
of −0.3 (versus 0.2 in the placebo group) at month 6 and −0.5
(95% CI: –0.9, –0.1) at month 24 (ref. 20).
PTC GL-3 inclusions
During the first 6 months of the study, the mean (SD) number
of GL-3 inclusions per PTC decreased from baseline in males
with the classic phenotype treated with migalastat (−0.8
[−0.78]; 95% CI: –1.8, 0.1; n= 5) (Fig. 1d; individual values in
Table S1). Conversely, PTC GL-3 inclusions increased (mean
[SD], 0.3 [0.94]; 95% CI: –0.6, 1.2; n= 7) during that period
in those receiving placebo. Upon switching from placebo to
migalastat at month 6, PTC GL-3 inclusions decreased by a
mean (SD) of −0.7 (0.91) (95% CI: –1.7, 0.2; n= 6) over the
next 6 months in these patients. These results mirror those
reported for the overall amenable FACETS population, in
which PTC GL-3 inclusions decreased over 6 months of
migalastat treatment (mean [SE], −0.25 [0.10]; n= 25) and
increased (mean [SE], 0.07 [0.13]; n= 20) over 6 months of
placebo treatment.20 In the overall amenable FACETS
population, a subsequent mean (SE) decrease in mean GL-3
inclusions per PTC of −0.33 (0.15; n= 17) was seen following
switch from placebo to migalastat at month 6.
Decreases in mean (SD) number of PTC GL-3 inclusions
were seen in other patients whether treated with migalastat
from month 0 to 6 (−0.1 [0.30]; 95% CI: –0.2, 0.0; n= 20) or
switched from placebo to migalastat at month 6 (change from
month 6 to 12; −0.1 [0.24]; 95% CI: –0.3, 0.1; n= 11)
(Fig. 1d). A small decrease was also noted in other patients
treated with placebo from month 0 to 6 (−0.05 [0.10]; 95%
CI: –0.1, 0.0; n= 13). Overall, the decreases in the other
patients subgroup were small, likely due to low baseline levels;
however, the magnitude of change with migalastat was twice
that of placebo.
GL-3 in glomerular cells
On the basis of qualitative assessments of kidney biopsy
samples, patients in the classic phenotype subgroup had either
a reduction or no change in GL-3 inclusions in glomerular
endothelial cells (3/9 decreased, 6/9 had no change),
mesangial cells (3/9 decreased, 6/9 had no change), and
podocytes (9/9 had no change) at month 12 compared with
baseline or month 6 (for patients switched from placebo to
migalastat). No patient showed increase in GL-3 in these cell
types after 6–12 months of migalastat treatment (Table S2).
A substantial portion of patients in the other patients
subgroup had a reduction in GL-3 in glomerular cells,
including mesangial cells (14/31), endothelial cells (8/31), and
podocytes (6/31) at month 12. One patient had an increase in
GL-3 in mesangial cells. The remaining patients experienced
no change in GL-3 inclusions in these cells after 6–12 months
of migalastat treatment.
Plasma lyso-Gb3
Migalastat was associated with a reduction in plasma lyso-Gb3
in both subgroups, with a considerable reduction observed in
the classic phenotype subgroup. The average (SD) change
from baseline to month 24 in plasma lyso-Gb3 was −36.8
(35.78) nmol/L (95% CI: −69.9, −3.7; n= 7) for males with
the classic phenotype and −7.66 (20.27) nmol/L (95% CI:
−16.6, 1.3; n= 22) for other patients (Fig. 1e; individual
values in Table S1). Notably, mean (SD) baseline lyso-Gb3
levels were 99.8 (35.28; n= 7) nmol/L in the classic phenotype
subgroup versus 29.3 (48.32; n= 24) nmol/L in the other
patients subgroup.
PBMC α-Gal A activity
Within the classic phenotype subgroup, 6 months of
randomized treatment with migalastat led to a mean (SD)
increase in PBMC α-Gal A activity of 2.2 (3.0) 4 MU/h/mg
(95% CI: −0.5, 5.0; n= 7), whereas treatment with placebo
led to a substantially smaller increase (0.1 [0.1] 4 MU/h/mg;
95% CI: 0.0, 0.2; n= 7). Increase in PBMC α-Gal A activity
was sustained during open-label migalastat; mean (SD)
change from baseline to month 24 was 2.6 (2.3) 4 MU/h/
mg (95% CI: 0.8, 4.4; n= 9). Changes in PBMC α-Gal A
activity appeared to be more variable in the other
patients subgroup due to the small number of male patients;
mean (SD) change from baseline to month 24 was 2.7 (9.8)
4 MU/h/mg (95% CI:–21.7, 27.1; n= 3).
Adverse events
The most frequently reported adverse event that occurred
during migalastat treatment was headache in both the classic
phenotype (4/14 [29%]) and other patients (15/36 [42%])
subgroups. The other patients subgroup did not report any
other adverse events that occurred in ≥20% of patients,
whereas diarrhea, procedure pain, and vertigo were reported
in ≥20% of patients in the classic phenotype subgroup
(Table S3).
DISCUSSION
Fabry disease is associated with a wide spectrum of disease
progression and clinical phenotypes, ranging from the most
severe, classic phenotype to an asymptomatic phenotype in a
subset of female patients.1 Newborn screening studies
estimate the frequency of the classic phenotype as up to 1
in 22,570 males.27 Patients with the classic phenotype
typically have onset of symptoms during childhood or
adolescence, followed by multiorgan complications that can
progress to organ failure.1 Therefore, early treatment initia-
tion is crucial in this patient population. Current treatment
guidelines and consensus recommendations recommend ERT
treatment for all males ≥16 years old with classic Fabry
disease, even if they are asymptomatic, presenting a high
treatment burden.28
In a previously published report from the phase 3 FACETS
study, patients with Fabry disease who have amenable
variants were shown to benefit from treatment with migala-
stat.20 The results presented here provide additional evidence
for the beneficial effects of migalastat in male patients with
the classic phenotype—the most severe form of Fabry disease.
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In vitro assay data suggest that all patients with Fabry disease
and amenable variants, including those with the classic
phenotype, would benefit from migalastat treatment, as
migalastat increases α-Gal A activity in the lysates of cells
expressing mutated enzyme.4 This hypothesis is supported by
our data, which demonstrate reduction in cardiac mass,
improvements in GSRS-D, stabilization of eGFRCKD-EPI,
reduction in PTC GL-3 inclusions, plasma lyso-Gb3, and
PBMC α-Gal A activity in male patients with the classic
phenotype treated with migalastat for up to 24 months.
Compared with published data for male patients with Fabry
disease, the results of this analysis suggest that patients treated
with migalastat had better renal29–32 and cardiac33,34 out-
comes than that historically reported for untreated patients.
Historical studies of untreated males report an annualized
change in eGFR of up to −12.2 mL/min/1.73 m2.29–32
Comparatively, the annualized change in eGFRCKD-EPI was
−0.3 mL/min/1.73 m2 in the subgroup of patients with the
classic phenotype treated with migalastat in FACETS (Fig. 2a).
For LVMi, studies of untreated males report annualized
increases ranging from 4.1 to 8.0 g/m2 (refs. 33,34), compared
with an annualized change of −10.4 g/m2 with migalastat in
males with the classic phenotype (Fig. 2b). Furthermore,
migalastat appears to provide potential cardiac benefit
compared with ERT (Fig. 2) (refs.12,19,34–36). This is further
supported by the greater efficacy of migalastat versus ERT in
reducing cardiac mass at month 18 in a phase 3, open-label,
randomized clinical trial (ATTRACT; NCT01218659)
(ref. 19). The benefit of migalastat on cardiac structure may
reflect the broad tissue distribution of migalastat as an orally
administered small molecule, including penetration into
cardiac tissue.19,23 However, the mechanism by which
migalastat reduces LVMi is unknown. Clearance of GL-3
deposits from cardiomyocytes and vascular endothelial cells
may have contributed to the mass reduction; GL-3 clearance
from the latter could also lead to enhanced regional
myocardial perfusion and function, influencing the dynamic
of left ventricular remodeling. Additionally, it appeared that
reduction in LVMi was due to a reduction in both wall



















































































































Fig. 2 Comparisons of published data for male patients with Fabry disease. Annualized changes in (a) renal function and (b) LVMi as reported in the
literature for male patients who are either untreated or have been treated with migalastat or ERT. aChange from baseline calculated using the weighted
average for end-stage renal disease subgroups (n= 128 males with non-end-stage renal disease and n= 17 males with end-stage renal disease). eGFR
estimated glomerular filtration rate, ERT enzyme replacement therapy, LVMi left ventricular mass index.
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Further investigations are needed to obtain more definitive
understanding of the pathophysiology of cardiomyopathy in
Fabry disease and the effects of migalastat on cardiac tissues.
Elevated plasma lyso-Gb3 levels have become recognized as
a diagnostic indicator for Fabry disease, especially for classic
Fabry patients.37 Consistent with previous reports,37,38 base-
line plasma lyso-Gb3 levels were highly elevated in male
patients with the classic phenotype in FACETS. Migalastat
was associated with substantial reduction in lyso-Gb3 in this
patient subgroup. Despite the reduction, plasma lyso-Gb3
levels remained elevated above the normal ranges after
24 months of treatment.38 It has been reported that lyso-
Gb3 levels decreased but did not normalize despite years of
ERT in male patients with the classic phenotype.37
In our study, the classic phenotype was defined as males
with multiorgan system involvement and residual PBMC α-
Gal A activity <3% of normal (Table 1). Of note, one of the
GLA variants associated with the classic phenotype, p.
Arg301Gln (p.R301Q), was originally identified in a Japanese
male and characterized as a cardiac variant, a milder atypical
variant with late-onset cardiac manifestations limited to the
heart.39 Since then, at least one case of a more severe
phenotype has been associated with this variant, including a
45-year-old male patient who had end-stage renal disease in
addition to cardiomyopathy; this patient benefited from
double heart and kidney transplant.40 The patient with the p.
Arg301Gln variant in our study had multiorgan disease (stage
3 chronic kidney disease [eGFR 56mL/min/1.73 m2], abnor-
mal LVMi [137 g/m2]) and PBMC α-Gal A activity 1.9% of
WT, thus fulfilling the criteria for inclusion in the classic
phenotype subgroup.
Our study includes a descriptive analysis of the baseline
disease characteristics and clinical outcomes of two patient
subgroups in FACETS; the other patients subgroup consists
predominantly, though not exclusively, of females. One
potential limitation of our study is that outcomes based on
indirect comparisons across studies should be interpreted
with caution because of potentially confounding factors, such
as variations in study design, inclusion/exclusion criteria,
baseline demographics, and disease severity. In addition, the
results reported for males with the classic phenotype from the
FACETS study are derived from post hoc analyses in a
relatively small group of patients observed for up to
24 months, a relatively short study duration for long-term
data, given the progressive nature of Fabry disease. Lastly,
GSRS-D has not been validated specifically in Fabry disease,
although it has demonstrated reliability, stability, and
construct validity across a range of GI disorders. No GI
symptom rating scale has been validated in Fabry disease.
Despite these limitations, our data show beneficial effects in
male patients with the classic phenotype, and provide support
for the use of migalastat in all patients with amenable GLA
variants regardless of disease severity.
In conclusion, migalastat, a first-in-class oral pharmacologic
chaperone, has previously demonstrated clinical benefits in
patients with Fabry disease and amenable GLA variants.20 The
data reported here establish that migalastat benefited male
patients with the classic phenotype. During the phase 3
FACETS trial, migalastat treatment increased endogenous α-
Gal A activity, stabilized eGFR, reduced LVMi, improved
diarrhea symptoms, and reduced PTC GL-3 inclusions and
plasma lyso-Gb3 in male patients with migalastat-amenable
GLA variants leading to the classic phenotype of Fabry
disease.
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